Perceived contraindications to thrombolytic treatment in acute myocardial infarction. A survey at a teaching hospital

Emergency Medicine Journal

Volumn 15, Issue 5, 1998, Pages 329-331

  Wald, David S ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ST RICHARD S HOSPITAL   (United Kingdom)

Author keywords

Acute myocardial infarction; Thrombolytic treatment

Indexed keywords

FIBRINOLYTIC AGENT;

ABDOMINAL AORTA ANEURYSM; ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BLEEDING TENDENCY; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; COMA; COMORBIDITY; DIABETIC RETINOPATHY; EMERGENCY MEDICINE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; INTERVIEW; INTRACRANIAL ANEURYSM; INTRACRANIAL TUMOR; MENSTRUATION; PEPTIC ULCER; PHYSICIAN; PREGNANCY; RESUSCITATION; TEACHING HOSPITAL; TOOTH EXTRACTION; VEIN PUNCTURE;

ENGLAND; HEALTH CARE SURVEYS; HOSPITALS, TEACHING; HUMANS; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; THROMBOLYTIC THERAPY;

EID: 0031686564     PISSN: 13510622     EISSN: None     Source Type: Journal    
DOI: 10.1136/emj.15.5.329     Document Type: Article

References (20)

1. Gruppo Italiano per lo Studio Streptochinasi nell'Infarto Miocardico (Gissi). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-402.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-402.
3. FTT Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994,343:311-22.
4. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction and subdural hematoma after acute myocardial infarction and thrombolysis in myocardial infarction study. Thrombolysis in myocardial infarction, phase II, pilot and clinical trial. Circulation 1991;83:448-59.
5. Hood S, Bimie D, Curzio JL, et al. Wide variation in the use of thrombolytic therapy among junior doctors in south and central Scotland. Health Bull (Edinb) 1996;54:131-9.
6. Birkhead JS. Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. Myocardial infarction audit group. Heart 1997;78:28-33.
7. Wald DS. Thrombolysis after acute myocardial infarction. Lancet 1997,349:1551.
8. Levine MN, Goldhaber SZ, Califf RM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1992;102:364-73S.
9. Wilcox RG, Van der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1998,ii:525-30.
10. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990;335:427-31.
11. Van der Werf F, Arnold AER. Intravenous tissue plasminogen activater and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ 1988;297: 1374-9.
12. The International Study Group In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;339: 753-70.
13. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1993; 339:753-70.
14. Collins R, Peto R, Baigent C, et al. Asprin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-60.
15. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference, Ann Intern Med 1980;93:141-4.
16. Sekyema YF, Baltazar RF. Is thrombolytic therapy safe during active menstruation? J Emerg Med 1995;13:345-8.
17. Conti CR. Is menstruation a contraindication to thrombolytic therapy? Clin Cardiol 1992;15:625-6.
18. Cross SJ, Lee HS, Rawles JM, et al. Safety of thrombolysis in associated cardiopulmonary resuscitation. BMJ 1991;303: 1242.
19. Tenaglia AN, Califf RM, Candela RJ, et al. Thrombolytic therapy in patients requiring cardiopulmonary resuscitaion. Am J Cardiol 1991;68:1015-9.
20. Higgs ER, Parfitt VJ, Harney BA, et al. Use of thrombolysis for acute myocardial infarction in the presence of diabetic retinopathy in the UK, and associated ocular haemorrhagic complications. Diabet Med 1995;12:426-8.